AB0 blood groups and oncological and functional outcomes in bladder cancer patients treated with radical cystectomy.


Journal

Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
ISSN: 2282-4197
Titre abrégé: Arch Ital Urol Androl
Pays: Italy
ID NLM: 9308247

Informations de publication

Date de publication:
27 Dec 2022
Historique:
received: 21 09 2022
accepted: 02 10 2022
entrez: 28 12 2022
pubmed: 29 12 2022
medline: 31 12 2022
Statut: epublish

Résumé

We investigated AB0 blood groups prevalence according to preoperative and pathological tumor characteristics, and their association with oncological outcomes, and renal function decline in a contemporary large cohort of bladder cancer (BCa) patients, who underwent radical cystectomy (RC) at a tertiary referral center. We retrospectively evaluated data of patients with histologically confirmed and clinically non metastatic BCa, who underwent RC between 2014 and 2021 at our Institution. Kaplan-Meier (KM) plots and Cox regression (CR) models tested the relationship between AB0 blood groups and local recurrence-, metastasis-, cancer specific mortality-, and overall mortality-free survival. Logistic regression (LR) models tested the association between AB0 blood groups and renal function decline, defined as an estimated Glomerular Filtration Rate (eGFR) < 60 mL/min, at post-operative day 1, discharge and 6- months of follow-up. Of 301 included patients, 128 (42.5%) had group A, 126 (41.9%) had group 0, 28 (9.3%) had group B, and 19 (6.3%) had group AB. Patients with group 0 developed higher rates of muscle- invasive BCa (p = 0.028) with high-grade features (p = 0.005) at last bladder resection, and less frequently received preoperative immunotherapy with Bacillus of Calmette-Guerin (p = 0.044), than their non-0 counterparts. Additionally, these patients harbored more advanced pathologic tumor stage at RC (p = 0.024). KM plots showed no differences among all tested cancer control outcomes between AB0 blood groups (p > 0.05 in all cases). Patients with group AB presented the lowest median eGFR at each time point. In multivariable LR analyses addressing renal function decline, group AB was independently associated with eGFR< 60 mL/min at discharge (Odds Ratio: 4.28, p = 0.047). Among AB0 blood groups, patients with group 0 exhibited the most aggressive tumor profile. However, no differences were recorded in recurrence or survival rates. Group AB independently predicted renal function decline at discharge.

Identifiants

pubmed: 36576469
doi: 10.4081/aiua.2022.4.428
doi:

Substances chimiques

Blood Group Antigens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

428-433

Auteurs

Alessandro Tafuri (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Department of Urology, "Vito Fazzi" Hospital, Lecce. aletaf@hotmail.it.

Andrea Panunzio (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy; Cancer and Prognostics Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec. panunzioandrea@virgilio.it.

Antonio Soldano (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. soldanoantonio@libero.it.

Giovanni Mazzucato (G)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. gio.mazzucato@gmail.com.

Paola Irene Ornaghi (PI)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. paolairene.ornaghi@gmail.com.

Giacomo Di Filippo (G)

Department of General and Hepatobiliary Surgery, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona. giacomo.difilippo90@gmail.com.

Alessandra Gozzo (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. la.ale.gozzo@gmail.com.

Nicola De Maria (N)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. nicola.demaria02@gmail.com.

Francesco Cianflone (F)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. fra1178@gmail.com.

Aliasger Shakir (A)

USC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles. aliasgershakir@gmail.com.

Zhe Tian (Z)

Cancer and Prognostics Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec. zhe.tian24@gmail.com.

Matteo Brunelli (M)

Department of Pathology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. matteo.brunelli@univr.it.

Antonio Benito Porcaro (AB)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. drporcaro@yahoo.com.

Vincenzo Pagliarulo (V)

Department of Urology, "Vito Fazzi" Hospital, Lecce. enzopagliarulo@yahoo.com.

Walter Artibani (W)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. prof.artibani@gmail.com.

Pierre I Karakiewicz (PI)

Cancer and Prognostics Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec. pierrekarakiewicz@gmail.com.

Alessandro Antonelli (A)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. alessandro_antonelli@me.com.

Maria Angela Cerruto (MA)

Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona. mariaangela.cerruto@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH